logo

For the Inventor, By the Inventor

Handa, Japan

Takafumi Ikeda

This inventor holds 12 USPTO granted patents. Top assignees: Pfizer Corporation, Pfizer Pharmaceuticals, Inc., Warner-Lambert Company. Active years: 1992-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takafumi Ikeda. Retrieved from https://idiyas.com/inventor/takafumi-ikeda-vpiok5ae

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 12

% Patents Active = 91.7

Average Co-Inventor Count = 2.4

ph-index = 3

Forward Citations = 28(Granted Patents)


Location History:

  • Handa, JP (1992 - 2001)
  • Aichi, JP (2002)
  • Aichi-ken, JP (2003)

Company Filing History:

goldMedal10 out of 4,489 
 
Pfizer Corporation
 patents
silverMedal1 out of 2 
 
Pfizer Pharmaceuticals, Inc.
 patents
bronzeMedal1 out of 2,538 
 
Warner-Lambert Company
 patents

Years Active: 1992-2003

Loading Chart...
12 patents (USPTO):Explore Patents
1. 6653313 - 1,4-dihydropyridine compounds as bradykinin antagonists (2003-11-25),
2. 6444677 - 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists (2002-09-03),
3. 6291520 - Hydroxamic acid and N-hydroxyurea derivatives and their use (2001-09-18),
4. 6156752 - Optically active 1,4-dihydropyridine compounds as bradykinin antagonists (2000-12-05),
5. 6131226 - 1,4-dihydropyridine compounds as bradykinin antagonists (2000-10-17),
6. 5861402 - 1,4-dihydropyridine compounds (1999-01-19),
7. 5541218 - Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as (1996-07-30),
8. 5521212 - Cyclopropyl N-hydroxyurea and N-hydroxyacetamides which inhibit (1996-05-28),
9. 5478822 - Tetrahydrobenzazepine derivatives which inhibit lipoxygenase (1995-12-26),
10. 5384320 - N-hydroxyurea derivatives which inhibit lipoxygenase (1995-01-24),
11. 5256789 - Antiinflammatory hydroxamic acids and N-hydroxyureas (1993-10-26),
12. 5104874 - Benzoquinone antiallergy and antinflammatory agents (1992-04-14),

Title: The Innovative Contributions of Takafumi Ikeda

Introduction

Takafumi Ikeda is a notable inventor based in Handa, Japan, recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 12 patents to his name, Ikeda's work primarily focuses on developing compounds that serve as bradykinin antagonists, critical for various therapeutic applications.

Latest Patents

Among his latest innovations, Ikeda has patented 1,4-dihydropyridine compounds, specifically those substituted with 5-membered heteroaryl groups, which demonstrate potential as bradykinin antagonists. These groundbreaking compounds are instrumental in advancing treatment options for a variety of medical conditions.

Career Highlights

Throughout his career, Takafumi Ikeda has been associated with prominent pharmaceutical companies, including Pfizer Corporation and Warner-Lambert Company. His work within these esteemed organizations has allowed him to hone his expertise in drug development and innovation, significantly contributing to the pharmaceutical landscape.

Collaborations

Ikeda's inventive journey has been marked by collaboration with notable co-workers, including Rodney W. Stevens and Mitsuhiro Kawamura. These partnerships have fostered a dynamic exchange of ideas, enhancing the creative process and leading to the successful development of numerous patents.

Conclusion

In conclusion, Takafumi Ikeda's contributions to the field of pharmaceuticals through his innovative inventions and collaborative efforts are commendable. His dedication to advancing medicinal chemistry continues to influence healthcare and improve patient outcomes, establishing him as a prominent inventor in the realm of bradykinin antagonists.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…